Weight may influence breast cancer drug response, study suggests
NCT ID NCT02095184
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether body weight affects how breast cancer responds to aromatase inhibitors (AIs) like Anastrozole and Letrozole. Researchers gave standard doses of these drugs to 42 postmenopausal women with hormone-sensitive breast cancer before surgery. The goal was to see if overweight or obese women had a different anti-proliferative response compared to normal-weight women. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anastrozole (Arimidex) and Letrozole (Femara)
What this could lead to
If successful, this could help doctors personalize aromatase inhibitor doses based on a patient's body weight, potentially improving treatment effectiveness for overweight or obese women with breast cancer.
What could go wrong
This was a small, early-stage study that was terminated, so results are limited. It may not provide clear answers, and findings may not apply to all breast cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States